<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04207554</url>
  </required_header>
  <id_info>
    <org_study_id>WF2019-01</org_study_id>
    <nct_id>NCT04207554</nct_id>
  </id_info>
  <brief_title>Clinical Investigation for the Preview® hCG Urine/Serum Combo Pregnancy Test</brief_title>
  <acronym>Preview® hCG</acronym>
  <official_title>Clinical Investigation for the Preview® hCG Urine/Serum Combo Pregnancy Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Wondfo Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nova Clinical Solutions, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou Wondfo Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the agreement of the test device (Preview® hCG
      Urine/Serum Combo Pregnancy Test) with the predicate device, the QuickVue+ hCG Combo Test.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall percent (%) agreement</measure>
    <time_frame>3 months</time_frame>
    <description>The primary endpoint is the overall percent (%) agreement, which is the percentage of total subjects where the test (Preview® hCG Urine/Serum Combo Pregnancy Test) and the reference test (QuickVue+ hCG Combo Test) agree.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive and negative percent agreement</measure>
    <time_frame>3 months</time_frame>
    <description>The secondary endpoint is the positive percent agreement and negative percent agreement.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Pregnancy Positive</arm_group_label>
    <description>Pregnant subjects within 11 weeks since the first day of last period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnancy Negative</arm_group_label>
    <description>Non-pregnant subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test Device-Strip Format</intervention_name>
    <description>Sponsor's investigational device</description>
    <arm_group_label>Pregnancy Negative</arm_group_label>
    <arm_group_label>Pregnancy Positive</arm_group_label>
    <other_name>Preview® hCG Urine/Serum Combo Pregnancy Test-Strip Format</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Test Device-Cassette Format</intervention_name>
    <description>Sponsor's investigational device</description>
    <arm_group_label>Pregnancy Negative</arm_group_label>
    <arm_group_label>Pregnancy Positive</arm_group_label>
    <other_name>Preview® hCG Urine/Serum Combo Pregnancy Test-Cassette Format</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Predicate Device</intervention_name>
    <description>Commercially available device</description>
    <arm_group_label>Pregnancy Negative</arm_group_label>
    <arm_group_label>Pregnancy Positive</arm_group_label>
    <other_name>QuickVue+ hCG Combo Test</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enroll healthy adult women of childbearing age.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult women of childbearing age.

          -  Who either request a pregnancy test, or require a pregnancy test for diagnostic
             studies or treatment.

          -  Signed and dated informed consent.

        Exclusion Criteria:

          -  Minors.

          -  Adults who are unable to independently give consent for study.

          -  Known pregnancy (i.e. - patient appears obviously pregnant).

          -  Recent miscarriage or abortion and yet to have 2 complete menstrual cycles before
             study start.

          -  History of ectopic pregnancy, fibroids, congenital uterine anomaly that causes an
             irregular-shaped uterus.

          -  Taken any of the medications of contraceptives containing estrogen in last two weeks.

          -  Hemodynamically unstable.

          -  Moderately to severely ill-appearing or in moderate to severe pain.

          -  Technically not possible to obtain blood or urine from the study subject.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy adult women of childbearing age.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui Liu, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Guangzhou Wondfo Biotech Co., Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huiqiang Wang, PhD</last_name>
    <phone>858-215-1688</phone>
    <email>jacky.wang@huanuoclinical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rui Liu, MS</last_name>
    <phone>858-368-3062</phone>
    <email>rui.liu@wondfousa.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Insitute of Clinical Research</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuvia Gomez</last_name>
      <phone>714-462-2000</phone>
      <email>ygomez@nicresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Phillip Le</last_name>
      <phone>714.462.2000</phone>
      <email>ple@nicresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael M Dao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Institute-Huntington Park</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Casey</last_name>
      <phone>323-588-1990</phone>
      <email>susana.casey@nritrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Rosa Bonilla</last_name>
      <phone>323-476-1987</phone>
      <email>Rosa.Bonilla@nritrials.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Leibowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Downtown L.A. Research Center, Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Research Institute-Westlake</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda Morales</last_name>
      <phone>213-413-2500</phone>
      <email>fernanda.morales@nritrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Mike Delgado</last_name>
      <phone>213-413-2500</phone>
      <email>mike.delgado@nritrials.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Leibowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Institute-Panorama City</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Delgado</last_name>
      <phone>818-532-6880</phone>
      <email>vanessa.delgado@nritrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Modesto Carrillo</last_name>
      <phone>818-532-6880</phone>
      <email>modesto.carrillo@nritrials.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Leibowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Institute-Santa Ana</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minie Mercado, LVN</last_name>
      <phone>714-599-8711</phone>
      <email>minie.mercado@nritrials.com</email>
    </contact>
    <investigator>
      <last_name>Mark Leibowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>WIDE L, GEMZELL CA. An immunological pregnancy test. Acta Endocrinol (Copenh). 1960 Oct;35:261-7.</citation>
    <PMID>13785019</PMID>
  </results_reference>
  <results_reference>
    <citation>Batzer FR. Hormonal evaluation of early pregnancy. Fertil Steril. 1980 Jul;34(1):1-13. Review.</citation>
    <PMID>6995156</PMID>
  </results_reference>
  <results_reference>
    <citation>Braunstein GD, Rasor J, Danzer H, Adler D, Wade ME. Serum human chorionic gonadotropin levels throughout normal pregnancy. Am J Obstet Gynecol. 1976 Nov 15;126(6):678-81.</citation>
    <PMID>984142</PMID>
  </results_reference>
  <results_reference>
    <citation>Braunstein GD, Vaitukaitis JL, Carbone PP, Ross GT. Ectopic production of human chorionic gonadotrophin by neoplasms. Ann Intern Med. 1973 Jan;78(1):39-45.</citation>
    <PMID>4734160</PMID>
  </results_reference>
  <results_reference>
    <citation>Catt KJ, Dufau ML, Vaitukaitis JL. Appearance of hCG in pregnancy plasma following the initiation of implantation of the blastocyst. J Clin Endocrinol Metab. 1975 Mar;40(3):537-40.</citation>
    <PMID>1117063</PMID>
  </results_reference>
  <results_reference>
    <citation>Lenton EA, Neal LM, Sulaiman R. Plasma concentrations of human chorionic gonadotropin from the time of implantation until the second week of pregnancy. Fertil Steril. 1982 Jun;37(6):773-8.</citation>
    <PMID>7115557</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>June 6, 2020</last_update_submitted>
  <last_update_submitted_qc>June 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>hCG</keyword>
  <keyword>IVD</keyword>
  <keyword>POCT</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

